Matthews Asia Dividend Active ETF ADVE 深 沪
等待开盘 10-21 09:30:00 美东时间
39.3442
+0.553
+1.43%
华盛通- 最 高39.39
- 今 开39.38
- 成交量 709股
- 最 低 39.3442
- 昨 收 38.7908
- 总市值 393.44万
- 52周最高 39.45
- 市盈率 静 --
- 换手率 0.71%
- 52周最低 26.6143
- 委 比 0.00%
- 总股本 10.00万
- 历史最高 39.45
- 量 比 0
- 振 幅 0.12%
- 历史最低 26.0215
- 每 手 1
- 风险率 2.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OUTFRONT and AWS USHER IN A NEW ERA FOR OUT-OF-HOME ADVERTISING
Marks a Major Step Toward Digitizing and Automating OOH with AI-Enabled Workflows NEW YORK, Oct. 15, 2025 /PRNewswire/ -- In a significant industry development, OUTFRONT Media Inc. (NYSE: OU...
10-15 21:25
RTX's Advanced Electronic Warfare prototype for F/A-18E/F Super Hornet passes critical review
New technology will accelerate advanced capability for the Navy's primary Strike Fighter PATUXENT RIVER, Md., Sept. 22, 2025 /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, has succes...
09-22 21:00
Tom Lee's Fundstrat Capital Files Preliminary Prospectus for Two New ETFs
NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Fundstrat Capital announced that it has filed a preliminary prospectus with the U.S. Securities and Exchange Commission ("SEC") for two new exchange-t...
08-25 19:30
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical compa...
07-02 20:00
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nas...
06-17 20:08
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today anno...
06-09 19:00
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New Engla...
06-02 20:04
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN, June 2, 2025 /PRNewswire/...
06-02 19:00
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovati...
05-27 14:00
Chimeric Therapeutics Reports Promising Results in ADVENT-AML Trial
Chimeric Therapeutics Ltd. ( ($AU:CHM) ) just unveiled an announcement. Chimeri...
05-15 11:27
